<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Track</th>
<th>Presentation Title</th>
<th>Speaker</th>
</tr>
</thead>
</table>
| 14-Nov | 06:00 - 07:00 AM | Clinical Lab Value              | Future Directions of Sepsis Management: The Emergence of Artificial Intelligence and the Laboratory Diagnostic Ecosystem | Nam K. Tran, PhD, HCLD (ABB), FACB  
Director of Clinical Chemistry, Special Chemistry/Toxicology, Point-of-Care Testing, and SARC Sections, Pathology and Laboratory Medicine, University of California, Davis, School of Medicine |
| 14-Nov | 06:00 - 07:00 AM | Emerging Technologies           | High Resolution View of D4Z4 Repeat Regions for Studying Facioscapulohumeral Muscular Dystrophy (FSHD) Using Whole Genome Optical Mapping | Alka Chaubey, PhD, FACMG  
Head of Cytogenomics and Laboratory Director, Perkin Elmer Genomics |
| 14-Nov | 07:30 - 08:30 AM | Opioid Crisis                   | Keynote Presentation: The Opioid Epidemic in Ohio - A Crime Laboratory Perspective   | Douglas Rohde, MS, F-ABC, MLT(ASCP)  
Supervisor of Chemistry & Toxicology, Lake County Crime Laboratory |
| 14-Nov | 09:00 - 10:00 AM | Emerging Technologies           | Discovering latent knowledge by applying machine learning techniques to QIAGEN resources | Jeff Green  
Staff Software Engineer, Qiagen |
| 14-Nov | 09:00 - 10:00 AM | Clinical Lab Value              | Drug testing in Regulatory Monitoring                                               | John Furman, PhD, MSN, COHN-S  
Director Washington Health Professional Services, Nursing Care Quality Assurance Commission, Washington State Department of Health |
| 14-Nov | 09:00 - 10:00 AM | Regulatory                      | The Role of Proficiency Testing in Achieving Global Outcomes for Hemoglobin A1c     | Paul M. Yip, PhD, FCACB, DABCC  
Head of Clinical Biochemistry, Sunnybrook Health Sciences Centre, and Associate Professor, Faculty of Medicine, University of Toronto |
| 14-Nov | 10:30 - 11:30 AM | Emerging Technologies           | Identifying the PIK3CA mutations that make a difference in breast cancer with the QIAGEN therascreen® PIK3CA RGQ PCR Kit | Benjamin Chaffey, PhD  
Global Product Manager, Oncology & Precision Diagnostics, QIAGEN |
<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
</table>
| 14-Nov| 10:30-11:30 AM | Clinical Lab Value            | Interferences with thyroid function tests and patient safety         | Damien Gruson, PhD  
Professor, Head of the Department of Clinical Biochemistry, Cliniques Universitaires Saint Luc                                                                  |
|       | 12:00-01:00 PM | Emerging Technologies         | Panel Discussion: Emerging technologies in laboratory medicine, opportunities and challenges | Anna Fuezery, PhD, DABCC, FCACB  
Corresponding member of IFCC C-MHBLM, North Sector POCT  
Medical Lead, Alberta Public Laboratories, Associate Clinical Professor of Laboratory Medicine, University of Alberta  
Damien Gruson, PhD  
Professor, Head of the Department of Clinical Biochemistry, Cliniques Universitaires Saint Luc |
| 14-Nov| 12:00-01:00 PM | Clinical Lab Value            | Thyroid autoimmunity and female infertility                          | David Unuane, MD, PhD  
Kliniekhoofd Endocrinologie - Diabetologie, University Hospital Brussels                                                                                          |
| 14-Nov| 01:30-02:30 PM | Clinical Lab Value            | Strategies to Improve Laboratory Stewardship                          | Gary Procop, MD, MS  
Medical Director & Co-Chair, Enterprise Laboratory Stewardship Committee, Enterprise Medical Operations, & Director of Microbiology, Virology, Mycology & Parasitology, Cleveland Clinic |